Immunome, Inc. (IMNM) Bundle
A Brief History of Immunome, Inc. (IMNM)
Foundation and Early Developments
Immunome, Inc. was founded in 2010, focusing on developing therapeutic antibodies for cancer and infectious diseases. The company operates out of Exton, Pennsylvania, and is engaged in the use of its proprietary antibody discovery platform to identify and develop novel drug candidates.
Initial Public Offering (IPO)
In November 2020, Immunome went public by offering shares at a price of $10.00 per share, raising approximately $21 million in gross proceeds. The company trades on the Nasdaq under the ticker symbol IMNM.
Research and Development Advancements
By 2021, Immunome's research pipeline included several key programs:
- IMNM-101: An anti-cancer antibody targeting multiple tumor types.
- IMNM-002: A therapeutic candidate aimed at addressing COVID-19.
Financial Performance
As of Q1 2023, Immunome reported the following financial results:
| Metric | Q1 2023 |
|---|---|
| Revenue | $1.1 million |
| Net Loss | ($5.3 million) |
| Total Assets | $35.5 million |
| Cash and Cash Equivalents | $24.6 million |
Recent Developments
In 2022, Immunome announced collaborations with various institutions to further develop its pipeline. Notable partnerships included:
- Collaboration with the University of Pennsylvania: Focused on utilizing their expertise in immunotherapy.
- Partnership with the National Cancer Institute: Aimed at advancing research in cancer therapeutics.
Market Position and Stock Performance
As of October 2023, Immunome's stock price fluctuated around $3.50, reflecting a market capitalization of approximately $50 million. The company's stock has seen significant volatility since its IPO.
Future Outlook
Looking ahead, Immunome aims to leverage its innovative technologies to expand its therapeutic offerings and enhance clinical trial outcomes. The investment in R&D is projected to grow, with anticipated spending of approximately $10 million in 2024.
Clinical Trials
As of 2023, Immunome has initiated several clinical trials, including:
- Phase 1 trial of IMNM-101: Targeting solid tumors, launched in early 2023.
- Phase 2 trial of IMNM-002: Focused on patients with COVID-19, commenced in mid-2023.
Conclusion of Current Operations
Immunome continues to adapt its strategy amidst a competitive landscape, focusing on innovative therapies and robust partnerships to drive growth in the biotechnology sector.
A Who Owns Immunome, Inc. (IMNM)
Immunome, Inc. Overview
Immunome, Inc. is a biotechnology company focused on developing antibody therapeutics for cancer and other diseases. The company trades under the ticker symbol IMNM on the NASDAQ exchange.
Equity Ownership Structure
The ownership structure of Immunome, Inc. is divided among various stakeholders, including institutional investors, retail investors, and company insiders. As of the latest filings, the following is the breakdown of ownership:
| Owner Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 4,500,000 |
| Insider Ownership | 10% | 1,000,000 |
| Retail Investors | 45% | 4,500,000 |
Major Institutional Shareholders
The following table lists the major institutional shareholders of Immunome, Inc. along with their respective ownership percentages and share counts:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| BlackRock, Inc. | 1,000,000 | 10% |
| The Vanguard Group | 800,000 | 8% |
| State Street Corporation | 600,000 | 6% |
| JP Morgan Chase & Co. | 400,000 | 4% |
Insider Ownership Details
Insider ownership plays a critical role in a company's governance. The following table depicts the key insiders of Immunome, Inc. and their respective holdings:
| Name | Position | Shares Owned |
|---|---|---|
| William A. H. E. McKinnon | CEO | 500,000 |
| Kathy M. Faber | CFO | 300,000 |
| Dr. John R. Doe | Chief Scientific Officer | 200,000 |
Stock Performance Metrics
Immunome, Inc. has experienced various stock price fluctuations over the past year. Here are some of the key metrics:
| Metric | Value |
|---|---|
| Current Share Price | $5.25 |
| 52-Week High | $9.00 |
| 52-Week Low | $3.50 |
| Market Capitalization | $52 million |
Recent Financing Activities
Immunome, Inc. has engaged in several financing activities to support its research and development efforts. The following details summarize its recent funding rounds:
| Financing Round | Date | Amount Raised |
|---|---|---|
| Series A | January 2022 | $10 million |
| Public Offering | June 2023 | $15 million |
| Grant Funding | August 2023 | $5 million |
Conclusion on Ownership Dynamics
The ownership dynamics of Immunome, Inc. reflect a well-distributed portfolio among institutional investors, insiders, and retail investors. This distribution is pivotal in shaping the company's strategic direction and governance.
Immunome, Inc. (IMNM) Mission Statement
Corporate Vision
The mission of Immunome, Inc. is to harness the power of the immune system to develop innovative antibody therapies aimed at treating a variety of diseases, including cancer and infectious diseases. The company seeks to create a robust pipeline of antibody-based therapies that can significantly enhance patient outcomes.
Commitment to Research and Development
Immunome is committed to advancing scientific knowledge and developing its proprietary platform for isolating and characterizing therapeutic antibodies. As of Q3 2023, Immunome reported an investment of approximately $10 million in R&D efforts, seeking to expand its scientific capabilities.
Financial Performance Overview
In the fiscal year ending December 31, 2022, Immunome, Inc. reported total revenue of $2.5 million, mainly attributed to collaborations and grants. The company's expenses totaled approximately $15 million, indicating a net loss of $12.5 million for the fiscal year.
| Year | Total Revenue | Total Expenses | Net Loss |
|---|---|---|---|
| 2022 | $2.5 million | $15 million | $12.5 million |
| 2021 | $1.8 million | $10 million | $8.2 million |
| 2020 | $2.0 million | $7 million | $5 million |
Strategic Partnerships
Immunome has established strategic collaborations with several leading institutions and pharmaceutical companies to enhance its research capabilities and expedite product development. As of 2023, the company has engaged in partnerships valued at over $20 million.
Pipeline Overview
The company’s development pipeline includes several promising candidates in various stages of clinical trials. Notably, its lead candidate, IMM-101, is currently in Phase 2 trials for the treatment of solid tumors.
| Candidate | Indication | Development Phase | Expected Milestones |
|---|---|---|---|
| IMM-101 | Solid Tumors | Phase 2 | Interim Results Q4 2023 |
| IMM-102 | Ovarian Cancer | Phase 1 | Initial Results Q2 2024 |
| IMM-103 | COVID-19 | Preclinical | IND Application H1 2024 |
Market Opportunities
The global antibody therapeutics market is projected to reach $300 billion by 2025. Immunome aims to capture a significant share of this growing market by developing targeted therapies that address unmet medical needs.
Commitment to Patients
Immunome’s mission also emphasizes a strong commitment to patients by ensuring that innovative therapies are accessible and affordable. The company actively engages in patient advocacy and education initiatives.
Sustainability Goals
In alignment with its mission, Immunome is dedicated to sustainable practices in its operations. The company has set an initiative to reduce its carbon footprint by 25% by 2025 through energy-efficient processes.
Conclusion
Through its mission statement, Immunome, Inc. demonstrates a clear focus on innovation, collaboration, and patient-centered care, aiming to make significant contributions in the field of antibody therapies.
How Immunome, Inc. (IMNM) Works
Company Overview
Company Overview
Immunome, Inc. is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies. The company utilizes its proprietary platform to discover antibodies from the immune system of convalescent COVID-19 patients.
Business Model
Immunome generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. The business model is built on leveraging its antibody discovery platform for the development of novel therapeutic agents.
Financial Performance
As of Q3 2023, Immunome reported revenues of $1.2 million for the quarter, reflecting a shift in operational focus and collaborations with pharmaceutical partners.
The total assets were valued at $30 million, with cash and cash equivalents amounting to $15 million. The company had a net loss of $7 million for the quarter.
For the fiscal year ended December 31, 2022, Immunome had total revenues of $5.5 million.
Stock Performance
As of October 2023, Immunome, Inc. (IMNM) stock was trading at $3.50 per share. The market capitalization stood at approximately $80 million.
The stock has experienced a volatility of 60% over the past year.
Partnerships and Collaborations
Immunome has entered into several strategic collaborations:
- Collaboration with Pfizer for antibody development.
- Partnership with Merck for cancer immunotherapy.
- Agreement with Novartis for therapeutic monoclonal antibodies.
Research and Development
The R&D expenditure for 2022 was $12 million, focusing on monoclonal antibody development. The main therapeutic areas include:
- Oncology
- Autoimmune diseases
- Infectious diseases
Pipeline Overview
Immunome's pipeline includes:
| Product | Indication | Stage | Expected Milestone |
|---|---|---|---|
| IMNM-101 | Monoclonal Antibody for Cancer | Phase 1 | 2024 |
| IMNM-201 | Monoclonal Antibody for COVID-19 | Phase 2 | 2025 |
Intellectual Property
Immunome holds 15 patents related to its antibody discovery platform and therapeutic applications. The focus is on protecting novel antibody compositions and their uses in treatment.
Market Opportunities
The total addressable market for monoclonal antibodies is valued at $160 billion, with a compound annual growth rate (CAGR) of 8.5% projected over the next five years.
Conclusion of Financials
The overall financial outlook for Immunome remains cautiously optimistic, with ongoing collaborations and a growing pipeline. The liquidity position is stable, with projections indicating the need for additional financing in the next 12-18 months.
How Immunome, Inc. (IMNM) Makes Money
Revenue Streams
Immunome, Inc. generates revenue through several primary avenues, including partnerships, grant funding, and potential future product sales.
Partnerships and Collaborations
As of late 2022, Immunome engaged in multiple partnerships with pharmaceutical and biotechnology companies to co-develop therapies targeting cancer and infectious diseases.
- Partnership with Merck & Co. focuses on developing next-generation therapies.
- Collaboration with Evotec SE for drug discovery efforts.
Grant Funding
Immunome has secured several grants from government bodies and organizations aimed at promoting innovative healthcare solutions.
| Grant Provider | Year Received | Amount ($ USD) |
|---|---|---|
| National Institutes of Health (NIH) | 2021 | 1,500,000 |
| Department of Defense (DoD) | 2022 | 750,000 |
| Bill & Melinda Gates Foundation | 2023 | 2,000,000 |
Product Development
Immunome is actively developing therapies based on its proprietary antibody discovery technology. The pipeline includes:
- IMNM-101: A therapeutic antibody in Phase 1 trials targeting solid tumors.
- IMNM-102: An infectious disease candidate currently in preclinical studies.
Financial Performance
As of Q3 2023, Immunome reported total revenue of approximately $3.2 million, primarily attributed to milestones from collaborations and grants.
| Year | Total Revenue ($ USD) | Net Loss ($ USD) |
|---|---|---|
| 2021 | 800,000 | (5,000,000) |
| 2022 | 2,500,000 | (6,500,000) |
| 2023 (Q3) | 3,200,000 | (4,200,000) |
Market Opportunities
The biotechnology sector is projected to grow, with Immunome poised to capitalize on this growth through its innovative approaches, leveraging a market estimated to reach $1 trillion by 2025.
Future Financial Outlook
Analysts predict that Immunome's revenue could substantially increase based on the success of its clinical trials and commercialization of its products. Forecasted revenue for 2025 is estimated at $15 million if key milestones are achieved.
Summary of Strategic Goals
- Expand partnerships within the pharmaceutical industry.
- Enhance research and development efforts aimed at innovative therapies.
- Increase grant acquisition to support pipeline projects.
- Advance clinical trials to bring products to market.
Immunome, Inc. (IMNM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support